Ventyx Biosciences to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq:VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.
Related news for (VTYX)
- MoBot’s Stock Market Highlights – 10/01/25 11:00 AM
- MoBot’s Stock Market Highlights – 10/01/25 10:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/08/25 03:00 PM
- Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease
- Breaking News: MoBot’s Latest Update as of 05/22/25 09:00 AM